RVTY:NYSERevvity, Inc. Analysis

Revvity is trading at $85.18, comfortably below its 20‑day SMA of 90.06 and the 50‑day SMA of 91.06, indicating short‑term weakness. The RSI of 38.6 and a bearish MACD histogram reinforce a near‑term bearish bias, while the price sits just above the calculated support level of $82.79. Volatility is elevated at 38% over the past 30 days and beta exceeds 1.5, suggesting the stock is more sensitive to market swings. Fundamentals show a high trailing PE of 41.3x versus the industry average of 25.3x, and a DCF‑derived fair value of $58.77, implying the stock is currently overvalued. Nevertheless, the company generates solid cash flow, a low dividend payout ratio of 13.6%, and an attractive forward PE of 14.2x, supporting a more favorable medium‑term outlook. Analyst consensus remains a “Buy” with a median target of $110, representing roughly 30% upside despite a recent Barclays downgrade to equal‑weight.
Long‑term prospects are underpinned by a diversified diagnostics portfolio and growth opportunities in genomics, though exposure to China and regulatory approvals add medium‑level risks. The dividend yield of 0.33% is sustainable given strong operating cash flow and modest leverage (debt‑to‑equity ~47). With a market cap near $9.5B and increasing trading volume, liquidity concerns are limited. Overall, the stock appears overvalued in the short term but offers upside potential as earnings improve and valuation compresses.